Skip to main content

24-10-2018 | Breast cancer | Video

IMpassion130 survival results

Peter Schmid discusses the progression-free and interim overall survival results for atezolizumab plus nab-paclitaxel in the setting of metastatic triple-negative breast cancer (5:24).

Funding for this video was provided in part by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits